Opinion: I worked on the CDC investigation of the anthrax letters. 25 years later, are we ready for the next biothreat?

“We’ve come a long way since the fall of 2001, but we find ourselves with recent widening gaps in public health readiness and mitigation,” writes Daniel B. Jernigan.
Sourcing & attribution. Newseze provides AI-curated summaries, narrative framing, and editorial analysis. The underlying reporting was contributed by STAT News; tap “Open original source” above to read their full reporting and support the contributing newsroom directly.
Across the aisle
Same story · other lanesHere's how the same story is being covered by outlets in other lanes. Read both — Newseze doesn't pick a side.
Newseze's algorithm reads the story and answers your question — calmly, factually, with source attribution. No comments, no flame wars — just answers.
No questions yet. Be the first.
Answers reflect Newseze's editorial framework applied under fair use (17 U.S.C. § 107). Not financial, legal, medical, or tax advice. Hate speech and racial slurs are blocked.
Related stories

Why it mattersThe administration is testing a constitutional power rarely used in decades—the rescission authority—to override spending Congress already appropriated, raising both enforcement questions and debate over the proper bound…
President Trump is canceling nearly $1 billion in spending approved by Congress, and most of the cuts are focused on HHS programs that serve refugees and unacco…

Why it mattersThe administration is testing constitutional limits on executive power over congressionally appropriated funds, with immediate consequences for federal refugee and unaccompanied minor services.
President Trump is canceling nearly $1 billion in spending approved by Congress, and most of the cuts are focused on HHS programs that serve refugees and unacco…

Why it mattersThe FDA approved Eli Lilly’s Onswik, a once-weekly basal insulin for adults with type 2 diabetes, offering patients an alternative to daily long-acting insulin injections.

Why it mattersPresident Trump’s nominee to lead the FDA was grilled by senators on hot button topics like China, vaccines, and abortion access